United States:
Cellular Pharmacodynamics Of A Novel Pyrrolo [3, 2-d] Pyrimidine Inhibitor Targeting Mitochondrial And Cytosolic One-Carbon Metabolism
08 May 2020
Kramer Levin Naftalis & Frankel LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Intellectual Property scientific advisor Khushbu Shah
co-authored an article titled "Cellular Pharmacodynamics of a
Novel Pyrrolo [3, 2-d] Pyrimidine Inhibitor Targeting Mitochondrial
and Cytosolic One-Carbon Metabolism" which was published in
Molecular Pharmacology on Jan. 1,
2020.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
"Patent Marking Regarding Software Medical Devices"
Marshall, Gerstein & Borun LLP
The IPO Law Journal recently published a paper titled "Patent Marking Regarding Software Medical Devices." The paper discusses an overview of patent marking-related case law...